alexa LC–MS/MS Method For Simultaneous Determination Of Thalidomide, Lenalidomide, Cyclophosphamide, Bortezomib, Dexamethasone And Adriamycin In Serum Of Multiple Myeloma Patients
ISSN: 2157-7064

Journal of Chromatography & Separation Techniques
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference and Exhibition on Advances in Chromatography & HPLC Techniques
July 13-14, 2017 Berlin, Germany

Feng Zhang and Wansheng Chen
Shanghai Changzheng Hospital, China
ScientificTracks Abstracts: J Chromatogr Sep Tech
DOI: 10.4172/2157-7064-C1-028
Abstract
Statement of the Problem: Multiple myeloma (MM), a malignant neoplastic serum-cell disorder, has been a serious threat to human health. The determination of 6 commonly used drug concentrations, including thalidomide (THD), lenalidomide (LND), cyclophosphamide (CTX), bortezomib (BTZ), dexamethasone (DXM) and adriamycin (ADM), in MM patients was of great clinical interest. Drug pharmacokinetic monitoring was important to ensure safety and efficacy during chemotherapy, but assays of one or two of these drugs in bio-fluids had been published. Methodology & Theoretical Orientation: We reported a method for the rapid and simultaneous measurement of the above therapeutics by liquid chromatography-tandem mass spectroscopy (LC–MS/MS) method with solid phase extraction. Analysis was performed on a Waters XBridge®BEH C18 column (2.5 μm, 2.1 mmx50 mm) with formic acid aqueous solution and acetonitrile as the mobile phase at flow rate 0.3 mL/min. Findings: All analytes showed good correlation coefficients (r>0.996), and LLOQ of THD, LND, CTX, BTZ, DXM and ADM were 4, 2, 2, 2, 2 and 2 ng/mL, respectively. The inter- and intra-day precisions and stability were expressed as variation coefficients within 15% and relative error less than 15%. Dilution effect, carryover and incurred sample reanalysis were in the acceptable levels. Conclusion & Significance: Validation method was investigated according to the 2015 edition Chinese Pharmacopoeia guidelines, as US FDA (2013, revision 1) required. The descried method was successfully applied to determine the clinical incurred serum samples from MM patients, and the tested results were also provided to the doctors for consideration. The LC–MS/MS based assay described in this article may improve future clinical studies evaluating common therapeutics for MM treatment.
Biography

Feng Zhang has her research interests in drug safety and efficacy determination. For Traditional Chinese Medicine (TCM), she has suggested a comprehensive strategy to understand the active marker compounds, therapeutic mechanisms and synergistic properties of TCM, by using LC-TOF/MS, LC-MS and LC-UV methods, metabolomics technology, as well as some conventional pharmacological analyses. For chemical drugs, she promotes better standardization of analytical practices in LC-MS based therapeutic drug monitoring analyses in clinical application. It is the key issue that makes the way of LC-MS into clinical routine laboratories.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords